The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
A simple method for assessing intestinal inflammation in Crohn's disease
Open accessAbstract
BACKGROUND AND AIMS: Assessing the presence and degree of intestinal inflammation objectively, simply, and reliably is a significant problem in gastroenterology. We assessed faecal excretion of calprotectin, a stable neutrophil specific marker, as an index of intestinal inflammation and its potential use as a screening test to discriminate between patients with Crohn's disease and those with irritable bowel syndrome. METHODS: The validity of faecal calprotectin as a marker of intestinal inflammation was assessed in 22 patients with Crohn's disease (35 studies) by comparing faecal excretions and concentrations using four day faecal excretion of 111 indium white cells. A cross sectional study assessed the sensitivity of faecal calprotectin concentration for the detection of established Crohn's disease (n=116). A prospective study assessed the value of faecal calprotectin in discriminating between patients with Crohn's disease and irritable bowel syndrome in 220 patients referred to a gastroenterology clinic. RESULTS: Four day faecal excretion of 111 indium (median 8.7%; 95% confidence interval (CI) 7–17%; normal <1.0%) correlated significantly (p<0.0001) with daily (median ranged from 39 to 47 mg; normal <3 mg; r =0.76–0.82) and four day faecal calprotectin excretion (median 101 mg; 95% CI 45–168 mg; normal <11 mg; r =0.80) and single stool calprotectin concentrations (median 118 mg/l; 95% CI 36–175 mg/l; normal <10 mg/l; r =0.70) in patients with Crohn's disease. The cross sectional study showed a sensitivity of 96% for calprotectin in discriminating between normal subjects (2 mg/l; 95% CI 2–3 mg/l) and those with Crohn's disease (91 mg/l; 95% CI 59–105 mg/l). With a cut off point of 30 mg/l faecal calprotectin has 100% sensitivity and 97% specificity in discriminating between active Crohn's disease and irritable bowel syndrome. CONCLUSION: The calprotectin method may be a useful adjuvant for discriminating between patients with Crohn's disease and irritable bowel syndrome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Changes of Intestinal Functions in Liver Cirrhosis
Fukui, H., & Wiest, R. (2016) · Inflammatory Intestinal Diseases · doi:10.1159/000444436 · Cited by 6,808
Development of a Crohn's Disease Activity Index
Best, W. R., Becktel, J. M., Singleton, J. W., & Kern, F. (1976) · Gastroenterology · doi:10.1016/s0016-5085(76)80163-1 · Cited by 3,152
Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study.
Best, W. R., Becktel, J. M., Singleton, J. W., & Kern, F. (1976) · PubMed · Cited by 3,147
A SIMPLE INDEX OF CROHN'S-DISEASE ACTIVITY
Harvey, R. F., & Bradshaw, J. M. (1980) · The Lancet · doi:10.1016/s0140-6736(80)92767-1 · Cited by 2,959
(2008) · Wiley eBooks · doi:10.1002/9781444303254 · Cited by 1,366
Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans
Bjarnason, I., Hayllar, J., Macpherson, A. N. D. J., & Russell, A. N. T. S. (1993) · Gastroenterology · doi:10.1016/0016-5085(93)90667-2 · Cited by 1,022
Self-citationEuropean Cooperative Crohn's Disease Study (ECCDS): Results of drug treatment
Malchow, H., Ewe, K., Brandes, J. W., Goebell, H., Ehms, H., Sommer, H., & Jesdinsky, H. (1984) · Gastroenterology · doi:10.1016/0016-5085(84)90409-8 · Cited by 933
Intestinal permeability: an overview
Bjarnason, I., Macpherson, A., & Hollander, D. (1995) · Gastroenterology · doi:10.1016/0016-5085(95)90708-4 · Cited by 927
Self-citationTumour necrosis factor alpha in stool as a marker of intestinal inflammation
Braegger, C. P., Nicholls, S., Murch, S. H., MacDonald, T. T., & Stephens, S. (1992) · The Lancet · doi:10.1016/0140-6736(92)90999-j · Cited by 683
Assessment of the Neutrophil Dominating Protein Calprotectin in Feces: A Methodologic Study
RØseth, A. G., Fagerhol, M. K., Aadland, E., & Schjønsby, H. (1992) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365529209011186 · Cited by 669
Self-citation
Cited by
Van Assche, G., Dignass, A., Panes, J., Beaugerie, L., Karagiannis, J., Allez, M., Ochsenkühn, T., Orchard, T., Rogler, G., Louis, E., et al. (2010) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2009.12.003 · Cited by 1,453
Laboratory markers in IBD: useful, magic, or unnecessary toys?
Vermeire, S., Van Assche, G., & Rutgeerts, P. (2006) · Gut · doi:10.1136/gut.2005.069476 · Cited by 952
van Rheenen, P. F., Van de Vijver, E., & Fidler, V. (2010) · BMJ · doi:10.1136/bmj.c3369 · Cited by 714
Evidence-based clinical practice guidelines for inflammatory bowel disease
Matsuoka, K., Kobayashi, T., Ueno, F., Matsui, T., Hirai, F., Inoue, N., Kato, J., Kobayashi, K., Kobayashi, K., Koganei, K., et al. (2018) · Journal of Gastroenterology · doi:10.1007/s00535-018-1439-1 · Cited by 698
Mosli, M. H., Zou, G., Garg, S. K., Feagan, S. G., MacDonald, J. K., Chande, N., Sandborn, W. J., & Feagan, B. G. (2015) · American Journal of Gastroenterology · doi:10.1038/ajg.2015.120 · Cited by 690
Langhorst, J., Elsenbruch, S., Koelzer, J., Rueffer, A., Michalsen, A., & Dobos, G. J. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01556.x · Cited by 591
Costa, F., Mumolo, M. G., Ceccarelli, L., Bellini, M., Romano, M. R., Sterpi, C., Ricchiuti, A., Marchi, S., & Bottai, M. (2005) · Gut · doi:10.1136/gut.2004.043406 · Cited by 550
Sipponen, T., Savilahti, E., Kolho, K.-L., Nuutinen, H., Turunen, U., & Färkkilä, M. (2008) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20312 · Cited by 480
The Utility of Biomarkers in the Diagnosis and Therapy of Inflammatory Bowel Disease
Lewis, J. D. (2011) · Gastroenterology · doi:10.1053/j.gastro.2010.11.058 · Cited by 458
Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease
Konikoff, M. R., & Denson, L. A. (2006) · Inflammatory Bowel Diseases · doi:10.1097/00054725-200606000-00013 · Cited by 453
Environmental enteropathy: critical implications of a poorly understood condition
Korpe, P. S., & Petri, W. A. (2012) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2012.04.007 · Cited by 449
Tibble, J. A., Sigthorsson, G., Foster, R., Forgacs, I., & Bjarnason, I. (2002) · Gastroenterology · doi:10.1053/gast.2002.34755 · Cited by 441
Self-citationDiagnostics of Inflammatory Bowel Disease
Nikolaus, S., & Schreiber, S. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.09.001 · Cited by 430
Pandolfino, J. E., Ghosh, S. K., Rice, J., Clarke, J. O., Kwiatek, M. A., & Kahrilas, P. J. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01532.x · Cited by 414
Diagnostic Precision of Fecal Calprotectin for Inflammatory Bowel Disease and Colorectal Malignancy
von Roon, A. C., Karamountzos, L., Purkayastha, S., Reese, G. E., Darzi, A. W., Teare, J. P., Paraskeva, P., & Tekkis, P. P. (2007) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01126.x · Cited by 401
Menees, S. B., Powell, C., Kurlander, J., Goel, A., & Chey, W. D. (2015) · American Journal of Gastroenterology · doi:10.1038/ajg.2015.6 · Cited by 391
Exercise-Induced Splanchnic Hypoperfusion Results in Gut Dysfunction in Healthy Men
van Wijck, K., Lenaerts, K., van Loon, L. J. C., Peters, W. H. M., Buurman, W. A., & Dejong, C. H. C. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022366 · Cited by 359
“The latter is considered a strong indicator of intestinal inflammation in specific, and has been found to correlate to other parameters of intestinal inflammation in inflammatory bowel disease [46] and enteropathy induced by non-steroidal anti-inflammatory drugs (NSAID) [47].”
BackgroundNacken, W., Roth, J., Sorg, C., & Kerkhoff, C. (2003) · Microscopy Research and Technique · doi:10.1002/jemt.10299 · Cited by 343
Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse
Gisbert, J. P., Bermejo, F., Pérez-Calle, J.-L., Taxonera, C., Vera, I., McNicholl, A. G., Algaba, A., López, P., López-Palacios, N., Calvo, M., et al. (2009) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20933 · Cited by 315
Takeuchi, K., Smale, S., Premchand, P., Maiden, L., Sherwood, R., Thjodleifsson, B., Bjornsson, E., & Bjarnason, I. (2006) · Clinical Gastroenterology and Hepatology · doi:10.1016/s1542-3565(05)00980-8 · Cited by 303
Self-citationRole of faecal calprotectin as non-invasive marker of intestinal inflammation
Costa, F., Mumolo, M. G., Bellini, M., Romano, M. R., Ceccarelli, L., Arpe, P., Sterpi, C., Marchi, S., & Maltinti, G. (2003) · Digestive and Liver Disease · doi:10.1016/s1590-8658(03)00381-5 · Cited by 289
Schoepfer, A. M., Trummler, M., Seeholzer, P., Seibold-Schmid, B., & Seibold, F. (2008) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20275 · Cited by 287
Waugh, N., Cummins, E., Royle, P., Kandala, N.-B., Shyangdan, D., Arasaradnam, R., Clar, C., & Johnston, R. (2013) · Health Technology Assessment · doi:10.3310/hta17550 · Cited by 286
Foell, D., Kucharzik, T., Kraft, M., Vogl, T., Sorg, C., Domschke, W., & Roth, J. (2003) · Gut · doi:10.1136/gut.52.6.847 · Cited by 279
Røseth, A. G., Aadland, E., & Grzyb, K. (2004) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520410007971 · Cited by 267
Keohane, J., O'Mahony, C., O'Mahony, L., O'Mahony, S., Quigley, E. M., & Shanahan, F. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.156 · Cited by 253
Shiotani, A., Kusunoki, H., Kimura, Y., Ishii, M., Imamura, H., Tarumi, K.-I., Manabe, N., Kamada, T., Hata, J., & Haruma, K. (2013) · Digestive Diseases and Sciences · doi:10.1007/s10620-013-2677-y · Cited by 26
Cepon‐Robins, T. J., Mallott, E. K., Recca, I. C., & Gildner, T. E. (2023) · American Journal of Biological Anthropology · doi:10.1002/ajpa.24574 · Cited by 12
Metadata
- Authors
- Tibble, J., Teahon, K., Thjodleifsson, B., Roseth, A., Sigthorsson, G., Bridger, S., Foster, R., Sherwood, R., Fagerhol, M., & Bjarnason, I.
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2000-10-01
- Volume
- 47
- Issue
- 4
- Pages
- 506-513
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- OpenAlex
- W2158926558
- Cited by
- 492
- References
- 40
- FWCI
- 4.82
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.